Potential prognostic long non-coding RNA identification and their validation in predicting survival of patients with multiple myeloma

Hu, Ai-Xin; Huang, Zhiyong; Zhang, Lin; Shen, Jian

doi:10.1177/1010428317694563

Cited by 24 publications

(25 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the meanwhile, it can interact with miRNA, protein coding genes, and individual lncRNA to contribute to the progression of various cancers (25,26). Over the years, many types of lncRNAs have also been revealed as a prognostic factor and therapeutic targets in many kinds of cancers (27)(28)(29)(30)(31)(32). The lncRNA XLOC_013703 is 2336 nt in length, located in chr20 (start: 24930648; end: 24932983; − strand), consisting of 2 exons.…”

Section: Discussionmentioning

confidence: 99%

Retracted: Decreased expression of long noncoding RNA XLOC_013703 promotes cell growth via NF‐κB pathway in multiple myeloma

Huang

et al. 2019

IUBMB Life

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are dysregulated in cancer and involved in oncogenic or tumor inhibitory processes. The aim of the study was to investigate the expression pattern of lncRNA XLOC_013703 in multiple myeloma (MM) and to evaluate its biological role and potential significance. We found that XLOC_013703 was significantly decreased in CD138 positive plasma cells and serum of MM patients compared to normal controls, and the decreased XLOC_013703 expression was correlated with β2‐MG, serum‐free light chain (s‐FLC) and revised international staging system. RNA‐fluorescence in situ hybridization results revealed that XLOC_013703 was distributed both in the nucleus and in the cytoplasm of MM cells including H929, RPMI8226, and U266. Overexpression of XLOC_013703 inhibited the proliferation of U266 cells and blocked the cell cycle in G1 stage, thus contributing to MM cell apoptosis. By contrast, knockdown of XLOC_013703 promoted the growth of H929 cells. Western blot analysis confirmed that the expression of p‐IκBα and nuclear P65 was substantially increased in shRNA transfection groups compared to control groups, whereas overexpression of XLOC_013703 reduced these expressions. In conclusion, we confirmed that the decreased expression of a novel lncRNA, XLOC_013703, in MM. XLOC_013703 was involved in MM cell survival and proliferation via nuclear factor‐κB pathway which represents a potential therapeutic target for MM. © 2019 IUBMB Life, 71(9):1240–1251, 2019

show abstract

Section: Discussionmentioning

confidence: 99%

Retracted: Decreased expression of long noncoding RNA XLOC_013703 promotes cell growth via NF‐κB pathway in multiple myeloma

Huang

et al. 2019

IUBMB Life

View full text Add to dashboard Cite

show abstract

“…Increasing evidence has suggested that dysregulation of lncRNAs is involved in the genesis and progression of MM (10,11). For instance, overexpression of lncRNA imprinted RNA near maternally expressed 3 promoted the osteogenic differentiation of mesenchymal stem cells from MM patients by targeting the transcription of bone morphogenetic protein 4 (22).…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, the dysregulated expression of lncRNAs has been indicated to be involved in the development and progression of various human cancer types, and these molecules are considered to be promising biomarkers and therapeutic agents for cancer (8,9). Numerous lncRNAs that have been implicated in MM progression and development by functioning as tumor suppressors or oncogenes (10,11). Consequently, understanding the underlying mechanism and biological functions of lncRNAs in MM may provide new approaches for its treatment.…”

Section: Introductionmentioning

confidence: 99%

Long intergenic non‑protein coding RNA 152 promotes multiple myeloma progression by negatively regulating microRNA‑497

Zhang

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

Long intergenic non-protein coding RNA 152 (LINC00152, also known as cytoskeleton regulator RNA) is reportedly involved in the development and progression of various types of human malignancy. However, the functional role of LINC00152 in multiple myeloma (MM) and the underlying molecular mechanisms have remained elusive. The present study aimed to investigate the role of LINC00152 in the genesis of MM and the potential molecular mechanisms. It was identified that the expression of LINC00152 was significantly upregulated in plasma cells from patients with MM vs. healthy subjects, and that a high expression of LINC00152 was correlated with a shorter overall survival in patients with MM. Functional assays demonstrated that knockdown of LINC00152 by transfecting MM cells with LINC00152-specific short hairpin RNA expression plasmids significantly inhibited cell proliferation by inducing cell cycle arrest at the G 0 /G 1 phase. Furthermore, knockdown of LINC00152 promoted caspase-3/9 activity and apoptosis in MM cells. In addition, knockdown of LINC00152 significantly attenuated tumor growth in mice bearing a myeloma xenograft. A luciferase reporter assay indicated that microRNA (miR)-497 is a direct target of LINC00152, and its expression levels were inversely correlated with those of LINC00152 in MM tissues. Furthermore, repression of miR-497 partly abrogated the inhibitory effects of LINC00152 knockdown on MM cells. Collectively, the results indicated that LINC00152 has an oncogenic effect in MM by targeting miR-497, and may be a novel diagnostic marker and therapeutic target for MM.

show abstract

“…Long noncoding RNAs (lncRNAs), which are long considered “junk RNAs” without biological functions, have been shown to provide considerable essential information for predicting the survival of multiple types of tumors [6-8]. Our previous study identified MM-associated lncRNAs using gene chip technology and bioinformatics databases.…”

Section: Introductionmentioning

confidence: 99%

High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple Myeloma

et al. 2019

View full text Add to dashboard Cite

Background: The aim of this study was to detect the expression of long noncoding RNA small nucleolar RNA host gene 18 (SNHG18) andsemaphorin 5A (SEMA5A) genes in multiple myeloma (MM) patients and to explore the correlation of the expression of these genes with the clinical characteristics and prognosis of MM patients. Methods: Forty-seven newly diagnosed MM, 18 complete remission MM, 13 refractory/relapse MM, and 22 iron deficiency anemia (serving as control) samples were extracted at the Department of Hematology, Second Aﬃliated Hospital of Xian Jiaotong University between January 2015 and December 2016. The clinical features of the MM patients are summarized. Real-time quantitative PCR was performed to analyze the relative expression levels of the SNHG18 and SEMA5Agenes. The clinical characteristics and overall survival (OS) of the MM patients were statistically analyzed while measuring different levels of SNHG18 and SEMA5Agene expression. At the same time, the correlation between the expression of SNHG18 and SEMA5A was also analyzed. Results: The analysis confirmed that SNHG18 and its possible target gene SEMA5A were both highly expressed in newly diagnosed MM patients. After analyzing the clinical signiﬁcance of SNHG18 and SEMA5A in MM patients, we found that the expression of SNHG18 and SEMA5A was related to the Durie-Salmon (DS), International Staging System (ISS), and Revised International Staging System (R-ISS) classification systems, and the Mayo Clinic Risk Stratification for Multiple Myeloma (mSMART; p < 0.05). Moreover, we observed a significant difference in OS between the SNHG18/SEMA5A high expression group and the low expression group. We found a positive correlation between SNHG18 and SEMA5A expression (r = 0.709, p < 0.01). Surprisingly, the expected median OS times of both the SNHG18 and SEMA5Ahigh expression groups were significantly decreased, which was in contrast to those of both the SNHG18 and SEMA5Alow expression groups and the single-gene high expression group (p < 0.05). Conclusion: High expression of both SNHG18 and SEMA5A is associated with poor prognosis in patients with MM.

show abstract

Potential prognostic long non-coding RNA identification and their validation in predicting survival of patients with multiple myeloma

Cited by 24 publications

References 45 publications

Retracted: Decreased expression of long noncoding RNA XLOC_013703 promotes cell growth via NF‐κB pathway in multiple myeloma

Retracted: Decreased expression of long noncoding RNA XLOC_013703 promotes cell growth via NF‐κB pathway in multiple myeloma

Long intergenic non‑protein coding RNA 152 promotes multiple myeloma progression by negatively regulating microRNA‑497

High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple Myeloma

Contact Info

Product

Resources

About